ZA833686B - Human human hybridomas for cervical carcinoma - Google Patents

Human human hybridomas for cervical carcinoma

Info

Publication number
ZA833686B
ZA833686B ZA833686A ZA833686A ZA833686B ZA 833686 B ZA833686 B ZA 833686B ZA 833686 A ZA833686 A ZA 833686A ZA 833686 A ZA833686 A ZA 833686A ZA 833686 B ZA833686 B ZA 833686B
Authority
ZA
South Africa
Prior art keywords
human
hybridomas
cervical carcinoma
monoclonal antibodies
clnh5
Prior art date
Application number
ZA833686A
Other languages
English (en)
Inventor
Hideaki Hagiwara
Mark C Glassy
Harold H Handley
Hagiwara Yoshihide
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of ZA833686B publication Critical patent/ZA833686B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA833686A 1982-05-21 1983-05-23 Human human hybridomas for cervical carcinoma ZA833686B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP57084843A JPS58201994A (ja) 1982-05-21 1982-05-21 抗原特異的ヒト免疫グロブリンの生産方法

Publications (1)

Publication Number Publication Date
ZA833686B true ZA833686B (en) 1984-09-26

Family

ID=13842073

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA833686A ZA833686B (en) 1982-05-21 1983-05-23 Human human hybridomas for cervical carcinoma

Country Status (13)

Country Link
EP (1) EP0109441B1 (mo)
JP (2) JPS58201994A (mo)
AT (1) ATE114189T1 (mo)
AU (1) AU560595B2 (mo)
CZ (1) CZ280677B6 (mo)
DE (1) DE3382764T2 (mo)
DK (1) DK164510C (mo)
FI (1) FI86077C (mo)
HU (1) HU190908B (mo)
IN (1) IN157982B (mo)
SK (1) SK279249B6 (mo)
WO (1) WO1983004313A1 (mo)
ZA (1) ZA833686B (mo)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247538A (en) * 1982-05-21 1988-12-28 Mark C. Glassy Human-human hybridomas for solid tumors
US4618577A (en) * 1983-02-09 1986-10-21 The Regents Of The University Of California Human-human hybridoma, CLNH5
US4939240A (en) * 1983-03-04 1990-07-03 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
ATE56046T1 (de) * 1983-03-04 1990-09-15 Health Research Inc Monoklonale antikoerper gegen humane brustkarzinomzellen und ihre verwendung in der diagnose und therapie.
US4613576A (en) * 1983-03-09 1986-09-23 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies to cancer cells
US4693966A (en) * 1983-03-11 1987-09-15 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies from lymphocytes of patients with malignant melanoma
GB2140030A (en) * 1983-04-08 1984-11-21 Kureha Chemical Ind Co Ltd Monoclonal antibody to human urinary bladder cancer
EP0162070A1 (en) * 1983-11-25 1985-11-27 The University Of Melbourne Cell line and monoclonal antibody
NZ210867A (en) * 1984-01-31 1989-01-06 Litton Bionetics Inc Tumour-specific monoclonal antibodies, production thereof and use
AU4070685A (en) * 1984-03-30 1985-10-03 Board Of Trustees Of The Leland Stanford Junior University Monoclonal antibody specific for human basal cell surfaces
US4886745A (en) * 1984-03-30 1989-12-12 Syntex Inc. Monoclonal antibody specific for human basal cell surface antigen
JPS6133125A (ja) * 1984-07-25 1986-02-17 Morinaga & Co Ltd ヒト単クロ−ン性抗肺ガン細胞抗体
US4761377A (en) * 1984-10-15 1988-08-02 The Regents Of The University Of California Human-human hybrid cell lines that produce antibodies against antigenic determinants on cancer cells
EP0183876A1 (en) * 1984-11-27 1986-06-11 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal antibodies for endotoxin core and their use
US5106746A (en) * 1985-05-22 1992-04-21 E. I. Du Pont De Nemours And Company Process for the in vitro immunization of human splenocytes against tumor associated antigens
US5776093A (en) * 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
JPH0655680B2 (ja) * 1985-10-26 1994-07-27 萩原 義秀 悪性腫瘍用ヒトモノクロナル抗体複合剤
EP0222360A3 (en) * 1985-11-12 1989-03-15 Biotherapeutics Inc. A method of producing a patient-specific cytotoxic reagent and composition
JPH0767388B2 (ja) * 1986-01-13 1995-07-26 三菱化学株式会社 抗体産生細胞株の樹立方法
AU7165891A (en) * 1989-12-18 1991-07-18 Board Of Regents, The University Of Texas System Tumor-specific, cell surface-binding monoclonal antibodies
US5281710A (en) * 1990-08-01 1994-01-25 The Scripps Research Institute Dynemicin analogs: synthesis, methods of preparation and use
JPH04346792A (ja) * 1991-05-22 1992-12-02 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体のアミノ酸配列及びそれをコードするｄｎａ塩基配列
EP0528663B1 (en) * 1991-08-16 1997-10-29 Kabushiki Kaisha Toshiba Monoclonal antibody to a synaptophysin
DE69839517D1 (de) 1997-08-15 2008-07-03 Chugai Pharmaceutical Co Ltd Präventiva oder arzneien enthaltend neutralisierende anti-il6-rezeptor antikörper zur reduktion urinären proteins bei systemischen lupus erythematosus
DE60039893D1 (mo) 1999-08-23 2008-09-25 Chugai Pharmaceutical Co Ltd
WO2001024626A1 (en) 1999-10-01 2001-04-12 Chugai Seiyaku Kabushiki Kaisha Prevention and treatment of diseases associated with blood coagulation
WO2002064159A1 (fr) 2001-02-07 2002-08-22 Chugai Seiyaku Kabushiki Kaisha Remedes contre les tumeurs affectant les organes hematopoietiques
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
MXPA04007924A (es) 2002-02-14 2005-05-17 Chugai Pharmaceutical Co Ltd Formulaciones en solucion que contienen anticuerpo.
WO2004019966A1 (ja) 2002-08-27 2004-03-11 Chugai Seiyaku Kabushiki Kaisha タンパク質溶液製剤の安定化方法
WO2004024752A1 (ja) 2002-09-11 2004-03-25 Chugai Seiyaku Kabushiki Kaisha タンパク質精製方法
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
EP2228445A1 (en) 2003-06-18 2010-09-15 Chugai Seiyaku Kabushiki Kaisha Fucose Transporter
JP4643450B2 (ja) 2003-08-08 2011-03-02 株式会社ペルセウスプロテオミクス 癌高発現遺伝子
AU2004295590B2 (en) 2003-12-03 2010-04-29 Chugai Seiyaku Kabushiki Kaisha Expression systems using mammalian beta-actin promoter
US20080206229A1 (en) 2003-12-12 2008-08-28 Koichiro Ono Modified Antibodies Recognizing Receptor Trimers or Higher Multimers
BRPI0506125B8 (pt) 2004-07-09 2021-05-25 Chugai Pharmaceutical Co Ltd anticorpo anti - glipicano 3, seu método de produção, polinucleotídeo, vetor e inibidor do crescimento de células
US20090061485A1 (en) 2004-12-22 2009-03-05 Chugai Seiyaku Kabushiki Kaisha Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
DK3050963T3 (da) 2005-03-31 2019-12-09 Chugai Pharmaceutical Co Ltd Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement
WO2006132363A1 (ja) 2005-06-10 2006-12-14 Chugai Seiyaku Kabushiki Kaisha メグルミンを含有するタンパク質製剤の安定化剤、およびその利用
CA2625773C (en) 2005-10-14 2015-05-12 Fukuoka University Inhibition of interleukin-6 (il-6) receptor promotes pancreatic islet transplantation
WO2007055378A1 (ja) 2005-11-14 2007-05-18 Cell Signals Inc. 調節性ｔ細胞の機能異常に基づく疾患の治療方法及び予防方法
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
EP1967209B1 (en) 2005-11-25 2012-06-06 Keio University Therapeutic agent for prostate cancer
US8771686B2 (en) 2006-01-27 2014-07-08 Chugai Seiyaku Kabushiki Kaisha Methods for treating a disease involving choroidal neovascularization by administering an IL-6 receptor antibody
DK2009101T3 (en) 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antibody modification method for purification of a bispecific antibody
EP2006381B1 (en) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Method for controlling blood pharmacokinetics of antibodies
JP5242382B2 (ja) 2006-04-14 2013-07-24 株式会社医学生物学研究所 エフェクター機能を有するポリペプチド変異体
AU2007255753B2 (en) 2006-06-08 2013-01-17 Chugai Seiyaku Kabushiki Kaisha Preventive or remedy for inflammatory disease
JPWO2007145227A1 (ja) 2006-06-14 2009-11-05 中外製薬株式会社 造血幹細胞増加促進剤
US20100150927A1 (en) 2006-07-13 2010-06-17 Chugai Seiyaku Kabushiki Kaisha Cell death inducer
JP5175729B2 (ja) 2006-07-21 2013-04-03 中外製薬株式会社 腎疾患治療剤
DE602006013809D1 (de) 2006-07-24 2010-06-02 Facultad De Medicina Universid Antikörper, Antikörperfragmente und scFv die an posttranslational modifizierte Neurotrophine binden
WO2008020586A1 (fr) 2006-08-14 2008-02-21 Forerunner Pharma Research Co., Ltd. diagnostic et traitement du cancer à l'aide de l'anticorps anti-desmogléine-3
EP2083017A4 (en) 2006-09-14 2011-01-12 Med & Biological Lab Co Ltd ANTIBODIES HAVING INCREASED ADCC ACTIVITY AND METHOD FOR PRODUCING THE SAME
MY162056A (en) 2006-10-12 2017-05-31 Univ Tokyo Diagnosis and treatment of cancer using anti -ereg antibody
EP3040347A3 (en) 2006-10-20 2016-09-21 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
US20100111851A1 (en) 2007-01-05 2010-05-06 The University Of Tokyo Diagnosis and treatment of cancer by using anti-prg-3 antibody
CN101951953A (zh) 2007-02-27 2011-01-19 株式会社未来创药研究所 含抗grp78抗体作为有效成分的药物组合物
WO2009001840A1 (ja) 2007-06-25 2008-12-31 Forerunner Pharma Research Co., Ltd. ADCC活性又はCDC活性を有する抗Prominin-1抗体
EP2174667B1 (en) 2007-07-26 2017-01-04 Osaka University Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient
CA2700701C (en) 2007-09-26 2020-12-29 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
EP2196220B1 (en) 2007-10-02 2014-12-03 Chugai Seiyaku Kabushiki Kaisha Inhibting anti-IL-6 receptor antibody for treating graft-versus-host disease
WO2009054435A1 (ja) 2007-10-24 2009-04-30 Otsuka Chemical Co., Ltd. 増強されたエフェクター機能を有するポリペプチド
CN102112492B (zh) 2007-11-14 2015-02-25 中外制药株式会社 使用抗gpr49抗体的癌症的诊断和治疗
EP2853544A1 (en) 2007-11-15 2015-04-01 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody capable of binding to anexelekto, and use thereof
RU2596397C2 (ru) 2007-12-05 2016-09-10 Чугаи Сейяку Кабусики Кайся Терапевтическое средство от зуда
WO2009072604A1 (ja) 2007-12-05 2009-06-11 Chugai Seiyaku Kabushiki Kaisha 抗nr10抗体、およびその利用
US20110262425A1 (en) 2007-12-12 2011-10-27 National Cancer Center Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
SG187457A1 (en) 2008-01-11 2013-02-28 Univ Tokyo Anti-cldn6 antibody
NZ717429A (en) 2008-04-11 2018-07-27 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
EP2116261A1 (en) 2008-05-07 2009-11-11 Institut Pasteur Sub-region of a plasmodium protein with improved vaccine potential and medical uses thereof
WO2009147781A1 (ja) 2008-06-02 2009-12-10 国立大学法人東京大学 抗がん剤
KR101665729B1 (ko) 2008-06-05 2016-10-12 국립연구개발법인 고쿠리츠간켄큐센터 신경침윤 억제제
WO2009154025A1 (ja) 2008-06-20 2009-12-23 国立大学法人岡山大学 酸化LDL/β2GPI複合体に対する抗体及びその用途
BRPI0923652A2 (pt) 2008-12-26 2016-10-18 Forerunner Pharma Res Co Ltd diagnóstico e tratamento de câncer usando anticorpo anti-lgr7
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
US8455249B2 (en) 2009-05-01 2013-06-04 The University Of Tokyo Highly effective anti-cadherin antibody for induction of antibody-dependent cellular cytotoxicity in vivo
EP2436397B1 (en) 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component
MY161541A (en) 2009-07-31 2017-04-28 Shin Maeda Cancer metastasis inhibitor
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
PT2535358T (pt) 2010-02-10 2018-02-23 Perseus Proteomics Inc Anticorpo anti-caderina marcado com metal radioativo
WO2011105573A1 (ja) 2010-02-26 2011-09-01 株式会社未来創薬研究所 抗icam3抗体およびその用途
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
PL2578231T3 (pl) 2010-05-28 2023-01-16 Chugai Seiyaku Kabushiki Kaisha Środek wzmacniający przeciwnowotworową odpowiedź limfocytów t
KR20140014077A (ko) 2010-10-25 2014-02-05 리전츠 오브 더 유니버스티 오브 미네소타 교모세포종의 치료를 위한 치료 조성물
EP3708586A1 (en) 2010-10-29 2020-09-16 Perseus Proteomics Inc. Anti-cdh3 antibody having high internalization capacity
EP2735315B1 (en) 2011-07-19 2019-10-02 Chugai Seiyaku Kabushiki Kaisha Stable protein-containing preparation containing argininamide or valinamide
EP2749572A4 (en) 2011-08-23 2015-04-01 Chugai Pharmaceutical Co Ltd NEW ANTI-DDR1 ANTIBODY WITH ANTITUMORACTIVITY
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
JP6291254B2 (ja) 2011-10-28 2018-03-14 中外製薬株式会社 癌幹細胞特異的分子
MX359775B (es) 2011-10-31 2018-10-10 Chugai Pharmaceutical Co Ltd Molecula enlazada al antigeno que tiene conjugacion regulada entre cadena ligera y cadena pesada.
HK1206386A1 (en) 2012-04-04 2016-01-08 Perseus Proteomics Inc. Conjugate of anti-cdh3 (p-cadherin) antibody and drug
WO2014007402A1 (ja) 2012-07-06 2014-01-09 京都府公立大学法人 眼細胞の分化マーカーおよび分化制御
EP2902489B9 (en) 2012-09-27 2018-02-07 Chugai Seiyaku Kabushiki Kaisha Fgfr3 fusion gene and pharmaceutical drug targeting same
EP3009518B1 (en) 2013-06-11 2020-08-12 National Center of Neurology and Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
WO2015099127A1 (ja) 2013-12-27 2015-07-02 中外製薬株式会社 Ｆｇｆｒゲートキーパー変異遺伝子およびそれを標的とする医薬
US20170362304A1 (en) 2014-08-20 2017-12-21 Chugai Seiyaku Kabushiki Kaisha Method for measuring viscosity of protein solution
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
EP4269440A3 (en) 2015-02-27 2024-02-28 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
AU2018240938A1 (en) 2017-03-24 2019-10-10 Zenyaku Kogyo Co., Ltd. Anti-IgM/B cell surface antigen bispecific antibody
WO2019078344A1 (ja) 2017-10-20 2019-04-25 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
EP3747469A4 (en) 2018-01-31 2022-03-23 Motokazu Kato THERAPEUTIC FOR ASTHMA WITH IL-6 INHIBITOR
US20220098290A1 (en) 2019-02-28 2022-03-31 Juntendo Educational Foundation Antibodies that bind to cleaved form of mutant calreticulin, and diagnostic, preventive, or therapeutic agent for myeloproliferative neoplasm
BR112021020525A2 (pt) 2019-04-17 2021-12-14 Chugai Pharmaceutical Co Ltd Agente terapêutico para câncer urológico que se caracteriza por ser administrado com inibidor de il-6 e inibidor de ccr2 em combinação
WO2020250940A1 (ja) 2019-06-11 2020-12-17 小野薬品工業株式会社 免疫抑制剤
US20230149555A1 (en) 2020-04-06 2023-05-18 PhotoQ3 Inc. Medicament for killing tumor cells
MX2023000854A (es) 2020-07-28 2023-02-15 Chugai Pharmaceutical Co Ltd Formulacion de jeringa precargada con aguja con protector de aguja que contiene nuevo anticuerpo modificado.
CA3192768A1 (en) 2020-08-27 2022-03-03 Juntendo Educational Foundation Anti-cleaved mutant calr-cd3 bispecific antibody and pharmaceutical composition
WO2022191306A1 (ja) 2021-03-12 2022-09-15 中外製薬株式会社 重症筋無力症の治療または予防用の医薬組成物
CN118043031A (zh) 2021-10-04 2024-05-14 诺华股份有限公司 表面活性剂稳定剂
US12460015B2 (en) 2021-12-01 2025-11-04 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical formulation comprising aqueous solution of antibody
TW202342097A (zh) 2022-02-25 2023-11-01 學校法人順天堂 抗突變calr抗體與其他藥劑組合而成之醫藥
WO2025198912A1 (en) 2024-03-21 2025-09-25 Hoffmann-La Roche Inc. Methods of treating myasthenia gravis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982001461A1 (en) * 1980-07-18 1982-05-13 Leland Stanford Junior Univ Human hybridomas,precursors and products
NZ198851A (en) * 1980-11-07 1984-07-31 Wistar Inst Stable,continuous human myeloma cell line capable of hybridisation with antibody-producing cells:production of hybrid cell line

Also Published As

Publication number Publication date
EP0109441A4 (en) 1986-09-22
SK356683A3 (en) 1998-08-05
CZ280677B6 (cs) 1996-04-17
DE3382764D1 (de) 1994-12-22
EP0109441A1 (en) 1984-05-30
CZ356683A3 (en) 1995-11-15
FI840219A0 (fi) 1984-01-19
AU560595B2 (en) 1987-04-09
AU1772983A (en) 1983-12-16
HU190908B (en) 1986-12-28
DK164510C (da) 1992-11-23
JPS60501359A (ja) 1985-08-22
IN157982B (mo) 1986-08-09
JPS58201994A (ja) 1983-11-25
ATE114189T1 (de) 1994-12-15
DK164510B (da) 1992-07-06
FI86077C (fi) 1992-07-10
EP0109441B1 (en) 1994-11-17
SK279249B6 (sk) 1998-08-05
JPH0159878B2 (mo) 1989-12-20
DE3382764T2 (de) 1995-03-16
FI86077B (fi) 1992-03-31
DK25084A (da) 1984-01-20
FI840219L (fi) 1984-01-19
DK25084D0 (da) 1984-01-20
WO1983004313A1 (en) 1983-12-08

Similar Documents

Publication Publication Date Title
ZA833686B (en) Human human hybridomas for cervical carcinoma
EP0220858A3 (en) Monoclonal anti-human breast cancer antibodies, corresponding hybridomas, the production and use thereof
ES8705975A1 (es) Un metodo de deteccion o localizacion de celulas de carcinoma humano.
IL67721A (en) Hybridoma cell lines,their preparation and their use for the production of human monoclonal antibodies
AU589351B2 (en) Tumor specific monoclonal antibodies
JPS6447378A (en) Monoclonal antibody to black tumor related antigen, hybrid cell line for producing the same and use thereof
GB2128631A (en) Antibodies having dual specificities their preparation and uses therefor
EP0118365A3 (en) Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
JPS6413992A (en) Hybridoma
EP0419574A4 (en) Monoclonal antibodies to the light chain region of human factor xii and methods of preparing and using the same
MX9605895A (es) Anticuerpos monoclonales humanos especificos para antigeno de superficie de glioma independiente del ciclo celular.
JPS6413991A (en) Hybridoma
EP0232871A3 (en) Human monoclonal antibody, hybridoma producing the same and its use
EP0166458A3 (en) Monoclonal antibody capable of specifically distinguishing human hepato-carcinoma cells
IL86958A (en) Human monoclonal antibody igm 16-88, cell lines producing it and antigen recognized thereby
EP0278160A3 (en) Human monoclonal anti cancer antibodies, hybridoma cell lines producing them and their uses
ZA878077B (en) Murine hybridoma lym-2 and diagnostic antibody produced thereby